Non-Melanoma Skin Cancers Coverage from Every Angle

Michael K.K. Wong, MD, PhD, on KRT-232: First-in-Class Agent for Merkel Cell Carcinoma

Posted: Wednesday, June 24, 2020

Michael K.K. Wong, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a possible new treatment for patients with Merkel cell carcinoma: the MDM2 inhibitor KRT-232. It demonstrated monotherapy activity in p53 wild-type disease that did not respond to anti–PD-1/PD-L1 treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.